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background:  Low levels of high-density lipoprotein cholesterol (HDL-C) are associated with adverse cardiovascular (CV) outcomes in patients with 
acute coronary syndromes (ACS), but this relationship has not been explored in high-risk patients who do not undergo revascularization.
methods: Baseline HDL-C levels were analyzed in 9,064 patients from the TRILOGY ACS trial who underwent medical management for non-ST-
elevation ACS. The primary endpoint was the composite of CV death, MI or stroke through 30 months; secondary outcomes comprised individual 
composite components plus all-cause death. HDL-C was evaluated as a dichotomous variable: <30 mg/dL (very low, <0.78 mmol/L) vs. ≥30 mg/dL 
(higher) for all outcomes.
results: Patients with very low HDL-C were younger, more likely to be male, have diabetes, prior MI and other risk factors. The unadjusted 30-month 
risk of the primary endpoint was borderline significant for patients with very low vs. higher HDL-C, while unadjusted risks of CV and all-cause death 
were significantly higher among those with very low HDL-C (Table). After adjustment, very low HDL-C was associated with a significant increase in risk 
of all-cause and CV death.
Conclusion: After adjustment, very low baseline HDL-C was associated with significant risks of all-cause and CV death through 30 months in 
medically managed ACS patients, suggesting that they represent a high-risk subset for whom HDL-C-raising therapy should be explored in future trials 
to improve long-term prognosis. 
 
Table. Association of Baseline HDL-C Level (<30 or ≥30 mg/dL*) With Efficacy Outcomes
Event
HDL <30 mg/dL†
(n=1,070 [11.8%])
HDL ≥30 mg/dL†
(n=7,994 [88.2%])
Unadjusted HR
(95% CI)
HDL <30 vs. ≥30 mg/dL
Adjusted HR
(95% CI)
HDL <30 vs. ≥30 mg/dL
CV death, MI, or stroke 21.9 19.2 1.16 (0.99, 1.36) 1.10 (0.93, 1.30)
CV death 12.6 9.87 1.42 (1.15, 1.75) 1.34 (1.08, 1.67)
MI 13.7 11.2 1.17 (0.95, 1.45) 1.13 (0.91, 1.40)
Stroke 1.79 2.45 0.83 (0.47, 1.47) 0.86 (0.48, 1.56)
All-cause death 14.9 11.6 1.39 (1.15, 1.68) 1.31 (1.08, 1.60)
*HDL groupings based on recent published data in both ACS and stable CAD patients indicating that this cutpoint may identify a subgroup at 
higher risk than the nominal 40 mg/dL cutpoint.
†Kaplan-Meier event rate at 30 months (%).
CI, confidence interval; CV, cardiovascular; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; MI, myocardial infarction
